CN103134910A - Application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment - Google Patents
Application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment Download PDFInfo
- Publication number
- CN103134910A CN103134910A CN2013100413194A CN201310041319A CN103134910A CN 103134910 A CN103134910 A CN 103134910A CN 2013100413194 A CN2013100413194 A CN 2013100413194A CN 201310041319 A CN201310041319 A CN 201310041319A CN 103134910 A CN103134910 A CN 103134910A
- Authority
- CN
- China
- Prior art keywords
- solution
- pluronic
- chorioallantoic membrane
- application
- chick embryo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment as medicine carrying material. The application includes the steps of setting the Pluronic F-127 solution at 4 DEG C through still-setting method to dissolve the solution, configurating biological isotonic solution of certain concentration, and thus the medicine carrying material is obtained. The Pluronic F-127 solution is in liquid state in low temperature, and thus the solution can be mixed with tested medicine conveniently, and possibility of temperature-sensitive medicine degeneration is reduced to the greatest extent. The Pluronic F-127 solution is transparent when the solution is in solid state in high temperature, and thus chick embryo chorioallantoic membrane does not deform when the Pluronic F-127 solution is used and observation is convenient.
Description
Technical field
The present invention relates to biological technical field, specifically belong to pluronic (Pluronic) F-127 solution as the application of medicine carrying material in the chick chorioallantoic membrane experiment.
Technical background
Angiogenesis is the important step of tumor development, transfer.Therefore in recent years, the mechanism of Angiogenesis, the research and development of anti-angiogenic medicaments have become one of study hotspot of oncology.Chick chorioallantoic membrane (chick embryo chorioallantoic membrane, CAM) model is to use more living Animal Models in anti-angiogenic generation research.Compare not only because it is simple to operate, with low cost, and with mouse model, observe more convenient.
When testing, generally carry out topical by place fritter filter paper, plastic ring (usually sheared by pipettor gun head and form) etc. on CAM, but all there is certain defect in these methods.Observe Angiogenesis take chick chorioallantoic membrane as object, often need successive administration just can obtain experimental result in some days.Because CAM constantly grows up in this process, filter paper and plastic ring all can make it can't normal growth and be out of shape because of adhering on CAM, finally cause observing difficulty.In addition, because filter paper is opaque, bring more problems also can for the record of experimental result.
Pluronic F-127 is the polyoxyethylene polyoxypropylene ether segmented copolymer, and without physiologically active, without hemolytic, to the skin nonirritant, toxicity is little.Usually do the uses such as emulsifying agent and stabilizing agent, solubilizer, receipts promoter, slow-release material, solid dispersion.In cell was cultivated, the Pluronic F-127 of low concentration can reduce the mechanical damage that between cell, mutual friction brings.Through By consulting literatures, there is no Pluronic F-127 and be applied in blood vessel research experiment take CAM as model as drug administration carrier.
Summary of the invention
The object of the present invention is to provide the medicine carrying material in the anti-angiogenic generation experiment of a kind of CAM of being applicable to.This material is not only transparent, can be stretched arbitrarily along with the growth of CAM, can not make the CAM distortion, and is easy to observe.
The present invention uses as medicine carrying material Pluronic F-127 solution in the chick chorioallantoic membrane experiment.
Described Pluronic F-127 solution is that concentration is the biological isotonic solution of Pluronic F-127 of (w/v) 16%～30%.
The preparation method of this Pluronic F-127 solution, step is: Pluronic F-127 is added biological isotonic solution in proportion, in 4 ℃ of hold over night dissolvings, be configured to concentration and be the biological isotonic solution of the Pluronic F-127 of (w/v) 16%～30%.
The invention has the beneficial effects as follows:
1, this material matter is soft, transparent, can not affect the CAM growth, and administering effect is observed convenient.
2, this material at low temperature is in a liquid state, and is convenient to mix with trial medicine, and can reduces to greatest extent the possibility of responsive to temperature type medicine sex change; It is solid-state that high temperature is, and is convenient to topical.
3, Pluronic F-127 is without physiologically active, and without hemolytic, to the skin nonirritant, toxicity is little.Can not produce reaction, can not produce injury to CAM yet with trial medicine.
Description of drawings
The present invention is further described below in conjunction with drawings and Examples.
Fig. 1 is the experimental result (partly being dropping the present invention in figure in white filter paper indication circle regional) of the embodiment of the present invention 1.
Fig. 2 is the experimental result (part shown in ellipse in figure) of the embodiment of the present invention 2.
Embodiment
Embodiment 1:
In 4 ℃ of environment, getting concentration is the Pluronic F-127 solution 20 μ L of 20% (w/v), slowly is added to the content-addressable memory face.The chicken embryo records result with stereomicroscope in 38.5 ℃ after continuing in relative humidity 85% environment to cultivate 48h.The CAM growth is normal, without distortion, compares with the neighboring area that does not add Pluronic F-127 solution, and vessel density is unchanged.
Embodiment 2:
In 4 ℃ of environment, with Lucentis(chemical name: Ranibizumab, Roche Holding Ag's product, a kind of anti-angiogenic medicine for the treatment of old moist macular degeneration) be dissolved in the present invention that concentration is 20% (w/v), making the Lucentis final concentration is 100 μ M.Get 20 μ L and slowly be added to the content-addressable memory face.The chicken embryo records result with stereomicroscope in 38.5 ℃ after continuing in relative humidity 85% environment to cultivate 48h.Dosing zone vessel density obviously reduces.
Embodiment 3:
In this invention, Pluronic F-127 solution concentration is 25%(w/v), all the other are with embodiment 1.
Embodiment 4:
In this invention, Pluronic F-127 solution concentration is 25%(w/v), all the other are with embodiment 2.
Claims (3)
1.Pluronic F-127 solution is as the application of medicine carrying material in the chick chorioallantoic membrane experiment.
2. Pluronic F-127 solution as claimed in claim 1 is as the application of medicine carrying material in the chick chorioallantoic membrane experiment, it is characterized in that, described Pluronic F-127 solution is that mass/volume concentration is 16%～30% the biological isotonic solution of Pluronic F-127.
3. the preparation method of a Pluronic F-127 solution, it is characterized in that, step is: Pluronic F-127 is added biological isotonic solution in proportion, in the dissolving of 4 ℃ of hold over night, obtain mass/volume concentration and be 16%～30% the biological isotonic solution of Pluronic F-127.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100413194A CN103134910A (en) | 2013-02-04 | 2013-02-04 | Application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100413194A CN103134910A (en) | 2013-02-04 | 2013-02-04 | Application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103134910A true CN103134910A (en) | 2013-06-05 |
Family
ID=48495014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100413194A Pending CN103134910A (en) | 2013-02-04 | 2013-02-04 | Application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103134910A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108703826A (en) * | 2018-04-09 | 2018-10-26 | 复旦大学附属华山医院 | It is a kind of to be molded endovascular stent system at once |
| CN109100200A (en) * | 2018-08-15 | 2018-12-28 | 广州星燎生物科技有限公司 | A kind of histotomy production method based on M-CDX tumor formation model |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454589A (en) * | 2003-04-11 | 2003-11-12 | 西南药业股份有限公司 | Coenzyme Q10 aseptic freee-drying preparation for injection and its preparing method |
| CN101306197A (en) * | 2008-05-16 | 2008-11-19 | 上海市肿瘤研究所 | Administration system of plasminogen activator sustained and controlled release preparation, construction and use thereof |
-
2013
- 2013-02-04 CN CN2013100413194A patent/CN103134910A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454589A (en) * | 2003-04-11 | 2003-11-12 | 西南药业股份有限公司 | Coenzyme Q10 aseptic freee-drying preparation for injection and its preparing method |
| CN101306197A (en) * | 2008-05-16 | 2008-11-19 | 上海市肿瘤研究所 | Administration system of plasminogen activator sustained and controlled release preparation, construction and use thereof |
Non-Patent Citations (4)
| Title |
|---|
| 吴红棉等: "《珠母贝糖胺聚糖对鸡胚绒毛尿囊膜血管生成的影响》", 《中国药理学通报》, vol. 24, no. 3, 31 March 2008 (2008-03-31), pages 374 - 376 * |
| 杨丽霞等: "《当归、黄芪注射液对鸡胚绒毛尿囊膜血管生成的影响》", 《北京中医药大学学报》, vol. 30, no. 12, 31 December 2007 (2007-12-31), pages 839 - 842 * |
| 陈萍等: "《紫杉醇普朗尼克稳定化胶束的制备》", 《中国医院药学杂志》, vol. 32, no. 20, 31 October 2010 (2010-10-31), pages 1606 - 1610 * |
| 陈萍等: "《紫杉醇普朗尼克稳定化胶束的制备》", 《中国医院药学杂志》, vol. 32, no. 20, 31 October 2012 (2012-10-31), pages 1606 - 1610 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108703826A (en) * | 2018-04-09 | 2018-10-26 | 复旦大学附属华山医院 | It is a kind of to be molded endovascular stent system at once |
| CN109100200A (en) * | 2018-08-15 | 2018-12-28 | 广州星燎生物科技有限公司 | A kind of histotomy production method based on M-CDX tumor formation model |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Hydrogel cryopreservation system: an effective method for cell storage | |
| Enrione et al. | Edible scaffolds based on non-mammalian biopolymers for myoblast growth | |
| Chaji et al. | Bioprinted three-dimensional cell-laden hydrogels to evaluate adipocyte-breast cancer cell interactions | |
| Karzbrun et al. | Brain organoids—a bottom-up approach for studying human neurodevelopment | |
| Liu et al. | Electrospun core (HPMC–acetaminophen)–shell (PVP–sucralose) nanohybrids for rapid drug delivery | |
| CN101836659A (en) | Compound potassium hydrogen persulfate disinfectant | |
| De la Ossa et al. | Waste autochthonous tuscan olive leaves (Olea europaea var. olivastra seggianese) as antioxidant source for biomedicine | |
| An et al. | Wound-healing effects of mesenchymal stromal cell secretome in the cornea and the role of exosomes | |
| Ujilestari et al. | Formulation and characterization of self-nano emulsifying drug delivery systems of lemongrass (cymbopogon citratus) essential oil | |
| King et al. | Injectable pH thermo-responsive hydrogel scaffold for tumoricidal neural stem cell therapy for glioblastoma multiforme | |
| Pham et al. | Egg white alginate as a novel scaffold biomaterial for 3D salivary cell culturing | |
| CN103134910A (en) | Application of Pluronic F-127 solution in chick embryo chorioallantoic membrane experiment | |
| Levey et al. | Assessing the effects of VEGF releasing microspheres on the angiogenic and foreign body response to a 3D printed silicone-based macroencapsulation device | |
| CN105582019A (en) | Tilmicosin solid dispersing agent and preparation method thereof | |
| Kostenko et al. | Storable cell-laden alginate based bioinks for 3D biofabrication | |
| CN105018418B (en) | Human oocytes In-vitro maturation liquid containing Endothelin-1 and application | |
| Song et al. | Pharmacodynamics study of zedoary turmeric oil chitosan microspheres administered via arterial embolization | |
| CN102727579B (en) | A kind of pharmaceutical composition being used for the treatment of oral ulcer | |
| He et al. | Preparation and in vitro characterization of microneedles containing inclusion complexes loaded with progesterone | |
| Shan et al. | Decellularized Porcine Conjunctiva in Treating Severe Symblepharon | |
| CN104152404A (en) | Embryo heat resistance improving culture solution and using method thereof | |
| Zhao et al. | In vivo CaV3 channel inhibition promotes maturation of glucose-dependent Ca2+ signaling in human iPSC-islets | |
| Leong et al. | Effectiveness of Bioinks and the Clinical Value of 3D Bioprinted Glioblastoma Models: A Systematic Review | |
| CN103860572B (en) | The application of baicalin in the poisoning medicine of preparation treatment Ricin | |
| Lu et al. | Preparation and antimicrobial activity of a film-forming polyhexamethylene biguanide teat disinfectant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130605 |